Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units
February 13 2018 - 8:00AM
Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
today announced recent product launches from Athenex Pharmaceutical
Division (“APD”). These launches highlight the continued portfolio
growth with an emphasis on oncology or oncology supportive therapy,
a business strategy of Athenex’s commercial business as an
effective supplement to its progressing clinical pipeline focused
on oncology.
Athenex has brought the following products to market in its 503B
(outsourced sterile preparations) and Specialty (finished-dose
specialty injectable products) businesses:
503B Products
- Epinephrine 2 mg and 4 mg in 250 mL in 0.9% Normal Saline (2
SKUs)
- Norepinephrine 4 mg and 8 mg in 250 in 0.9% Normal Saline (2
SKUs)
Specialty Products
- Caspofungin Acetate for Injection 50 mg per vial; 70 mg per
vial (2 SKUs; vials)
- Doxorubicin 5 mL, 25 mL, 100 mL; (3 SKUs; vials)
- Etomidate Injection 20 mg per 10 mL; 40 mg per 20 mL; (2 SKUs;
vials)
- Gemcitabine for Injection 1 mg (1 SKU; vials)
- Paclitaxel Injection 30 mg per 5 mL; 100 mg per 16.7 mL; 300 mg
per 50 mL; (3 SKUs; vials)
Jeffrey Yordon, Athenex’s Chief Operating Officer and President
of APD, commented, “These product launches underscore a
continuation of our ongoing commitment to bring needed, quality
oncology products to market on both the 503B and Specialty
Injectables sides of our business. As part of a broader effort to
build our commercial platform and capabilities, we will continue to
look for opportunities to bring additional products focused mainly
on oncology and oncology supportive care therapies to our customers
throughout 2018 as well as generate additional revenue to help fund
our clinical programs.”
Athenex is committed to quality and product labeling innovation.
cGMP processes are followed for each of Athenex’s products, and a
Certificate of Analysis is provided for each batch of 503B products
so customers are able to see measurable results from repeatable
tests. Additionally, Athenex’s AccuraSEE, a proprietary and highly
differentiated approach to package and labeling, has a unique
design to give caregivers accurate information and reduce the risk
of medication errors.
About Athenex, Inc.Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery and development of next generation drugs for the
treatment of cancer. Athenex is organized around three
platforms, including an Oncology Innovation Platform, a Commercial
Platform and a Global Supply Chain Platform. Athenex’s Oncology
Innovation Platform generates clinical candidates through an
extensive understanding of kinases, including novel binding sites
and human absorption biology, as well as through the application of
Athenex’s proprietary research and selection processes in the lab.
The Company’s current clinical pipeline is derived from two
different platform technologies Athenex calls Orascovery
and Src Kinase Inhibition. The Orascovery platform is based on the
novel oral P-glycoprotein pump inhibitor molecule HM30181A, through
which Athenex is able to facilitate oral absorption of
traditional cytotoxics, which Athenex believes may offer
improved patient tolerability and efficacy as compared to IV
administration of the same cytotoxics. The Orascovery platform was
developed by Hanmi Pharmaceuticals and licensed
exclusively to Athenex for all major worldwide
territories except Korea, which is retained by Hanmi. The Src
Kinase Inhibition platform refers to novel small molecule compounds
that have multiple mechanisms of action, including the inhibition
of the activity of Src Kinase and the inhibition of tubulin
polymerization during cell division. Athenex believes the
combination of these mechanisms of action provides a broader range
of anti-cancer activity as compared to either mechanism of action
alone. Athenex’s employees worldwide are dedicated to improving the
lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan and multiple locations
in Chongqing, China.
Forward-Looking Statement Disclaimer/Safe Harbor
StatementExcept for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. Actual results might differ
materially from those explicit or implicit in the forward-looking
statements. Important factors that could cause actual results to
differ materially include: the development stage of our primary
clinical candidates and related risks involved in drug development,
clinical trials, regulation, manufacturing and commercialization;
our need to raise additional capital; competition; intellectual
property risks; risks relating to doing business in China; and the
other risk factors set forth from time to time in our SEC filings,
copies of which are available for free in the Investor Relations
section of our website at
http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon
request from our Investor Relations Department. We assume no
obligation and do not intend to update these forward-looking
statements, except as required by law.
CONTACT:Jim PolsonTel: +1-716-427-2952Athenex, Inc.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024